Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer

BACKGROUND: Tamoxifen use has been associated with increased risk of thromboembolic events (TEs) in women with breast cancer and women at high risk for the disease. Factor V Leiden (FVL) is the most common inherited clotting factor mutation and also confers increased thrombosis risk. We investigated...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Garber, Judy E., Halabi, Susan, Tolaney, Sara M., Kaplan, Ellen, Archer, Laura, Atkins, James N., Edge, Stephen, Shapiro, Charles L., Dressler, Lynn, Paskett, Electra M., Kimmick, Gretchen, Orcutt, James, Scalzo, Anthony, Winer, Eric, Levine, Ellis, Shahab, Nasir, Berliner, Nancy
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2010
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897879/
https://ncbi.nlm.nih.gov/pubmed/20554945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djq211
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars